{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:40:25Z","timestamp":1789926025272,"version":"4.0.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Capital\u2019s Funds for Health Improvement and Research","award":["CFH, 2020-2-40110"],"award-info":[{"award-number":["CFH, 2020-2-40110"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences","award":["CIFMS, 2020-I2M-C&T-B-006"],"award-info":[{"award-number":["CIFMS, 2020-I2M-C&T-B-006"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-069 and 2022-PUMCH-B-025"],"award-info":[{"award-number":["2022-PUMCH-C-069 and 2022-PUMCH-B-025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is an underrecognized cause of heart failure due to misfolded wild-type transthyretin (TTRwt) myocardial deposition. The development of wild-type TTR amyloid fibrils is a complex pathological process linked to the deterioration of homeostatic mechanisms owing to aging, plausibly implicating multiple molecular mechanisms. The components of amyloid transthyretin often include serum amyloid P, proteoglycans, and clusterin, which may play essential roles in the localization and elimination of amyloid fibrils. Oxidative stress, impaired mitochondrial function, and perturbation of intracellular calcium dynamics induced by TTR contribute to cardiac impairment. Recently, tafamidis has been the only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of ATTRwt-CM. In addition, small interfering RNAs and antisense oligonucleotides for ATTR-CM are promising therapeutic approaches and are currently in phase III clinical trials. Newly emerging therapies, such as antibodies targeting amyloid, inhibitors of seed formation, and CRISPR\u2012Cas9 technology, are currently in the early stages of research. The development of novel therapies is based on progress in comprehending the molecular events behind amyloid cardiomyopathy. There is still a need to further advance innovative treatments, providing patients with access to alternative and effective therapies, especially for patients diagnosed at a late stage.<\/jats:p>","DOI":"10.1007\/s10741-023-10380-9","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T04:39:29Z","timestamp":1705552769000},"page":"511-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy"],"prefix":"10.1007","volume":"29","author":[{"given":"Danni","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"10380_CR1","doi-asserted-by":"crossref","unstructured":"Porcari A, Fontana M, Gillmore JD (2022) Transthyretin cardiac amyloidosis. Cardiovasc Res","DOI":"10.1093\/cvr\/cvac119"},{"key":"10380_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583\u2013596","journal-title":"N Engl J Med"},{"key":"10380_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41598-018-37230-1","volume":"9","author":"AKR Dasari","year":"2019","unstructured":"Dasari AKR, Hughes RM, Wi S, Hung I, Gan Z, Kelly JW et al (2019) Transthyretin aggregation pathway toward the formation of distinct cytotoxic oligomers. Sci Rep 9:33","journal-title":"Sci Rep"},{"key":"10380_CR4","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1016\/j.cell.2021.08.013","volume":"184","author":"MR Sawaya","year":"2021","unstructured":"Sawaya MR, Hughes MP, Rodriguez JA, Riek R, Eisenberg DS (2021) The expanding amyloid family: structure, stability, function, and pathogenesis. Cell 184:4857\u20134873","journal-title":"Cell"},{"key":"10380_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","volume":"57","author":"MB Pepys","year":"2006","unstructured":"Pepys MB (2006) Amyloidosis. Annu Rev Med 57:223\u2013241","journal-title":"Annu Rev Med"},{"key":"10380_CR6","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73:2872\u20132891","journal-title":"J Am Coll Cardiol"},{"key":"10380_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","volume":"75","author":"GG Cornwell","year":"1983","unstructured":"Cornwell GG, Murdoch WL, Kyle RA, Westermark P (1983) Frequency and distribution of senile cardiovascular amyloid.\u00a0A clinicopathologic correlation. Am J Med 75:618\u2013623","journal-title":"Am J Med"},{"key":"10380_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J et al (2008) Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40:232\u2013239","journal-title":"Ann Med"},{"key":"10380_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM et al (2014) Left ventricular amyloid deposition in patients with Heart Failure and preserved ejection fraction. JACC Heart Fail 2:113\u2013122","journal-title":"JACC Heart Fail"},{"key":"10380_CR10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C et al (2015) Wild-type transthyretin amyloidosis as a cause of Heart Failure with preserved ejection fraction. Eur Heart J 36:2585\u20132594","journal-title":"Eur Heart J"},{"key":"10380_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C et al (2021) Prevalence and outcomes of concomitant aortic stenosis and Cardiac Amyloidosis. J Am Coll Cardiol 77:128\u2013139","journal-title":"J Am Coll Cardiol"},{"key":"10380_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/13506129.2017.1333956","volume":"24","author":"E Cariou","year":"2017","unstructured":"Cariou E, Bennani Smires Y, Victor G, Robin G, Ribes D, Pascal P et al (2017) Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis. Amyloid 24:101\u2013109","journal-title":"Amyloid"},{"key":"10380_CR13","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A et al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38:2879\u20132887","journal-title":"Eur Heart J"},{"key":"10380_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-pathol-052016-100200","volume":"12","author":"A Dogan","year":"2017","unstructured":"Dogan A (2017) Amyloidosis: insights from Proteomics. Annu Rev Pathol 12:277\u2013304","journal-title":"Annu Rev Pathol"},{"key":"10380_CR15","doi-asserted-by":"crossref","unstructured":"Buxbaum JN, Dispenzieri A, Eisenberg DS, Fandrich M, Merlini G, Saraiva MJM et al (2022) Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 1\u20137","DOI":"10.1080\/13506129.2022.2147636"},{"key":"10380_CR16","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387:2641\u20132654","journal-title":"Lancet"},{"key":"10380_CR17","volume-title":"GeneReviews(\u00ae)","author":"Y Sekijima","year":"1993","unstructured":"Sekijima Y (1993) Hereditary Transthyretin Amyloidosis. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds) GeneReviews(\u00ae). University of Washington, Seattle, Seattle (WA)"},{"key":"10380_CR18","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN et al (2014) Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 35:E2403\u20132412","journal-title":"Hum Mutat"},{"key":"10380_CR19","doi-asserted-by":"crossref","unstructured":"Gonzalez-Duarte A, Ulloa-Aguirre A (2021) A brief journey through protein misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis). Int J Mol Sci 22","DOI":"10.3390\/ijms222313158"},{"key":"10380_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1515\/bmc-2013-0038","volume":"5","author":"M Vieira","year":"2014","unstructured":"Vieira M, Saraiva MJ (2014) Transthyretin: a multifaceted protein. Biomol Concepts 5:45\u201354","journal-title":"Biomol Concepts"},{"key":"10380_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/cb100144v","volume":"5","author":"SJ Hyung","year":"2010","unstructured":"Hyung SJ, Deroo S, Robinson CV (2010) Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Biol 5:1137\u20131146","journal-title":"ACS Chem Biol"},{"key":"10380_CR22","doi-asserted-by":"publisher","first-page":"592644","DOI":"10.3389\/fnmol.2020.592644","volume":"13","author":"F Bezerra","year":"2020","unstructured":"Bezerra F, Saraiva MJ, Almeida MR (2020) Modulation of the mechanisms driving transthyretin amyloidosis. Front Mol Neurosci 13:592644","journal-title":"Front Mol Neurosci"},{"key":"10380_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jcpt.12145","volume":"39","author":"Y Sekijima","year":"2014","unstructured":"Sekijima Y (2014) Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther 39:225\u2013233","journal-title":"J Clin Pharm Ther"},{"key":"10380_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1021\/ar020073i","volume":"38","author":"SM Johnson","year":"2005","unstructured":"Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding Diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38:911\u2013921","journal-title":"Acc Chem Res"},{"key":"10380_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1126\/science.1079589","volume":"299","author":"P Hammarstr\u00f6m","year":"2003","unstructured":"Hammarstr\u00f6m P, Wiseman RL, Powers ET, Kelly JW (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299:713\u2013716","journal-title":"Science"},{"key":"10380_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"SA Hollingsworth","year":"2018","unstructured":"Hollingsworth SA, Dror RO (2018) Molecular dynamics simulation for all. Neuron 99:1129\u20131143","journal-title":"Neuron"},{"key":"10380_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/wcms.31","volume":"1","author":"A Barducci","year":"2011","unstructured":"Barducci A, Bonomi M, Parrinello M (2011) Metadynamics. WIREs Comput Mol Sci 1:826\u2013843","journal-title":"WIREs Comput Mol Sci"},{"key":"10380_CR28","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1021\/acs.jcim.2c00447","volume":"62","author":"S Zhou","year":"2022","unstructured":"Zhou S, Zou H, Wang Y, Lo GV, Yuan S (2022) Atomic mechanisms of transthyretin tetramer dissociation studied by molecular dynamics simulations. J Chem Inf Model 62:6667\u20136678","journal-title":"J Chem Inf Model"},{"key":"10380_CR29","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/bi301313b","volume":"52","author":"L Zhao","year":"2013","unstructured":"Zhao L, Buxbaum JN, Reixach N (2013) Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52:1913\u20131926","journal-title":"Biochemistry"},{"key":"10380_CR30","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.1141448","volume":"319","author":"WE Balch","year":"2008","unstructured":"Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease intervention. Science 319:916\u2013919","journal-title":"Science"},{"key":"10380_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ijbiomac.2020.10.199","volume":"166","author":"E Wieczorek","year":"2021","unstructured":"Wieczorek E, Kedracka-Krok S, Bystranowska D, Ptak M, Wiak K, Wygralak Z et al (2021) Destabilisation of the structure of transthyretin is driven by Ca(2). Int J Biol Macromol 166:409\u2013423","journal-title":"Int J Biol Macromol"},{"key":"10380_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/71197","volume":"7","author":"CP Schultz","year":"2000","unstructured":"Schultz CP (2000) Illuminating folding intermediates. Nat Struct Biol 7:7\u201310","journal-title":"Nat Struct Biol"},{"key":"10380_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.abb.2012.10.006","volume":"531","author":"M Tsytlonok","year":"2013","unstructured":"Tsytlonok M, Itzhaki LS (2013) The how\u2019s and why\u2019s of protein folding intermediates. Arch Biochem Biophys 531:14\u201323","journal-title":"Arch Biochem Biophys"},{"key":"10380_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0014-5793(01)02480-2","volume":"498","author":"MJ Saraiva","year":"2001","unstructured":"Saraiva MJ (2001) Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 498:201\u2013203","journal-title":"FEBS Lett"},{"key":"10380_CR35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/418729a","volume":"418","author":"CM Dobson","year":"2002","unstructured":"Dobson CM (2002) Getting out of shape. Nature 418:729\u2013730","journal-title":"Nature"},{"key":"10380_CR36","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41580-018-0060-8","volume":"19","author":"MG Iadanza","year":"2018","unstructured":"Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE (2018) A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol 19:755\u2013773","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10380_CR37","doi-asserted-by":"crossref","unstructured":"Nanev CN (2020) Evaluation of the critical nucleus size without using interface free energy. J Cryst Growth 535","DOI":"10.1016\/j.jcrysgro.2020.125521"},{"key":"10380_CR38","doi-asserted-by":"publisher","first-page":"035102","DOI":"10.1063\/1.3050295","volume":"130","author":"J Zhang","year":"2009","unstructured":"Zhang J, Muthukumar M (2009) Simulations of nucleation and elongation of amyloid fibrils. J Chem Phys 130:035102","journal-title":"J Chem Phys"},{"key":"10380_CR39","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s10741-022-10237-7","volume":"27","author":"P Morfino","year":"2022","unstructured":"Morfino P, Aimo A, Panichella G, Rapezzi C, Emdin M (2022) Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Fail Rev 27:2187\u20132200","journal-title":"Heart Fail Rev"},{"key":"10380_CR40","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1073\/pnas.1423174112","volume":"112","author":"KW Tipping","year":"2015","unstructured":"Tipping KW, Karamanos TK, Jakhria T, Iadanza MG, Goodchild SC, Tuma R et al (2015) pH-induced molecular shedding drives the formation of amyloid fibril-derived oligomers. Proc Natl Acad Sci U S A 112:5691\u20135696","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10380_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/jsbi.1998.4052","volume":"124","author":"S Inoue","year":"1998","unstructured":"Inoue S, Kuroiwa M, Saraiva MJ, Guimar\u00e3es A, Kisilevsky R (1998) Ultrastructure of familial amyloid polyneuropathy amyloid fibrils: examination with high-resolution electron microscopy. J Struct Biol 124:1\u201312","journal-title":"J Struct Biol"},{"key":"10380_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajpath.2010.11.015","volume":"178","author":"MJ Greene","year":"2011","unstructured":"Greene MJ, Sam F, Soo Hoo PT, Patel RS, Seldin DC, Connors LH (2011) Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol 178:61\u201368","journal-title":"Am J Pathol"},{"key":"10380_CR43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3109\/13506129709003838","volume":"4","author":"MB Pepys","year":"1997","unstructured":"Pepys MB, Booth DR, Hutchinson KL, Gallimore JR, Collins PM, Hoheneste E (1997) Amyloid P component. A critical review. Amyloid 4:274\u2013295","journal-title":"Amyloid"},{"key":"10380_CR44","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","volume":"92","author":"GA Tennent","year":"1995","unstructured":"Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92:4299\u20134303","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10380_CR45","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nm0897-855","volume":"3","author":"M Botto","year":"1997","unstructured":"Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A et al (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3:855\u2013859","journal-title":"Nat Med"},{"key":"10380_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR et al (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254\u2013259","journal-title":"Nature"},{"key":"10380_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/37.5.2522961","volume":"37","author":"S Inoue","year":"1989","unstructured":"Inoue S, Grant D, Leblond CP (1989) Heparan sulfate proteoglycan is present in basement membrane as a double-tracked structure. J Histochem Cytochem 37:597\u2013602","journal-title":"J Histochem Cytochem"},{"key":"10380_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jmb.2012.01.004","volume":"421","author":"AR Wyatt","year":"2012","unstructured":"Wyatt AR, Yerbury JJ, Dabbs RA, Wilson MR (2012) Roles of extracellular chaperones in amyloidosis. J Mol Biol 421:499\u2013516","journal-title":"J Mol Biol"},{"key":"10380_CR49","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM et al (2015) Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 373:1106\u20131114","journal-title":"N Engl J Med"},{"key":"10380_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fcvm.2015.00025","volume":"2","author":"TL Parry","year":"2015","unstructured":"Parry TL, Melehani JH, Ranek MJ, Willis MS (2015) Functional amyloid signaling via the inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure. Front Cardiovasc Med 2:25","journal-title":"Front Cardiovasc Med"},{"key":"10380_CR51","doi-asserted-by":"publisher","first-page":"H149","DOI":"10.1152\/ajpheart.00073.2021","volume":"321","author":"KT Dittloff","year":"2021","unstructured":"Dittloff KT, Iezzi A, Zhong JX, Mohindra P, Desai TA, Russell B (2021) Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression. Am J Physiol Heart Circ Physiol 321:H149\u2013H160","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10380_CR52","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.bpj.2016.09.010","volume":"111","author":"L Sartiani","year":"2016","unstructured":"Sartiani L, Bucciantini M, Spinelli V, Leri M, Natalello A, Nosi D et al (2016) Biochemical and Electrophysiological Modification of Amyloid Transthyretin on cardiomyocytes. Biophys J 111:2024\u20132038","journal-title":"Biophys J"},{"key":"10380_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fgene.2017.00058","volume":"8","author":"EP Barykin","year":"2017","unstructured":"Barykin EP, Mitkevich VA, Kozin SA, Makarov AA (2017) Amyloid beta modification: a key to the sporadic Alzheimer\u2019s Disease? Front Genet 8:58","journal-title":"Front Genet"},{"key":"10380_CR54","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.bpj.2019.09.004","volume":"117","author":"L Vugmeyster","year":"2019","unstructured":"Vugmeyster L, Au DF, Ostrovsky D, Kierl B, Fu R, Hu ZW et al (2019) Effect of post-translational modifications and mutations on amyloid-beta Fibrils Dynamics at N Terminus. Biophys J 117:1524\u20131535","journal-title":"Biophys J"},{"key":"10380_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/jcmm.12446","volume":"19","author":"A Henze","year":"2015","unstructured":"Henze A, Homann T, Serteser M, Can O, Sezgin O, Coskun A et al (2015) Post-translational modifications of transthyretin affect the triiodonine-binding potential. J Cell Mol Med 19:359\u2013370","journal-title":"J Cell Mol Med"},{"key":"10380_CR56","doi-asserted-by":"publisher","first-page":"11887","DOI":"10.1074\/jbc.M709638200","volume":"283","author":"JS Kingsbury","year":"2008","unstructured":"Kingsbury JS, Laue TM, Klimtchuk ES, Theberge R, Costello CE, Connors LH (2008) The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation. J Biol Chem 283:11887\u201311896","journal-title":"J Biol Chem"},{"key":"10380_CR57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s100480050081","volume":"2","author":"K Altland","year":"1999","unstructured":"Altland K, Winter P (1999) Potential treatment of transthyretin-type amyloidoses by sulfite. Neurogenetics 2:183\u2013188","journal-title":"Neurogenetics"},{"key":"10380_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10048-003-0160-1","volume":"5","author":"K Altland","year":"2004","unstructured":"Altland K, Winter P, Saraiva MJ, Suhr O (2004) Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin. Neurogenetics 5:61\u201367","journal-title":"Neurogenetics"},{"key":"10380_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbapap.2006.10.015","volume":"1774","author":"L Gales","year":"2007","unstructured":"Gales L, Saraiva MJ, Damas AM (2007) Structural basis for the protective role of sulfite against transthyretin amyloid formation. Biochim Biophys Acta 1774:59\u201364","journal-title":"Biochim Biophys Acta"},{"key":"10380_CR60","doi-asserted-by":"publisher","first-page":"9079","DOI":"10.1021\/bi050378f","volume":"44","author":"Q Zhang","year":"2005","unstructured":"Zhang Q, Kelly JW (2005) Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S\/V30M transgenic mice? Biochemistry 44:9079\u20139085","journal-title":"Biochemistry"},{"key":"10380_CR61","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1021\/bi030077a","volume":"42","author":"Q Zhang","year":"2003","unstructured":"Zhang Q, Kelly JW (2003) Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry 42:8756\u20138761","journal-title":"Biochemistry"},{"key":"10380_CR62","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0002-9440(10)63123-9","volume":"164","author":"Y Takaoka","year":"2004","unstructured":"Takaoka Y, Ohta M, Miyakawa K, Nakamura O, Suzuki M, Takahashi K et al (2004) Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met. Am J Pathol 164:337\u2013345","journal-title":"Am J Pathol"},{"key":"10380_CR63","doi-asserted-by":"publisher","first-page":"16041","DOI":"10.1038\/boneres.2016.41","volume":"4","author":"V Veldurthy","year":"2016","unstructured":"Veldurthy V, Wei R, Oz L, Dhawan P, Jeon YH, Christakos S (2016) Vitamin D, calcium homeostasis and aging. Bone Res 4:16041","journal-title":"Bone Res"},{"key":"10380_CR64","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/clinchem\/29.4.629","volume":"29","author":"BJ Scott","year":"1983","unstructured":"Scott BJ, Bradwell AR (1983) Identification of the serum binding proteins for iron, zinc, cadmium, nickel, and calcium. Clin Chem 29:629\u2013633","journal-title":"Clin Chem"},{"key":"10380_CR65","doi-asserted-by":"publisher","first-page":"9123","DOI":"10.1021\/bi700607z","volume":"46","author":"LE Wilkinson-White","year":"2007","unstructured":"Wilkinson-White LE, Easterbrook-Smith SB (2007) Characterization of the binding of Cu(II) and zn(II) to transthyretin: effects on amyloid formation. Biochemistry 46:9123\u20139132","journal-title":"Biochemistry"},{"key":"10380_CR66","doi-asserted-by":"publisher","first-page":"13744","DOI":"10.1038\/s41598-018-31808-5","volume":"8","author":"L Ciccone","year":"2018","unstructured":"Ciccone L, Fruchart-Gaillard C, Mourier G, Savko M, Nencetti S, Orlandini E et al (2018) Copper mediated amyloid-beta binding to transthyretin. Sci Rep 8:13744","journal-title":"Sci Rep"},{"key":"10380_CR67","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","volume":"121","author":"Y Sekijima","year":"2005","unstructured":"Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR et al (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121:73\u201385","journal-title":"Cell"},{"key":"10380_CR68","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jmb.2005.11.051","volume":"356","author":"K Sorgjerd","year":"2006","unstructured":"Sorgjerd K, Ghafouri B, Jonsson BH, Kelly JW, Blond SY, Hammarstrom P (2006) Retention of misfolded mutant transthyretin by the chaperone BiP\/GRP78 mitigates amyloidogenesis. J Mol Biol 356:469\u2013482","journal-title":"J Mol Biol"},{"key":"10380_CR69","doi-asserted-by":"publisher","first-page":"8312","DOI":"10.1074\/jbc.M809354200","volume":"284","author":"S Susuki","year":"2009","unstructured":"Susuki S, Sato T, Miyata M, Momohara M, Suico MA, Shuto T et al (2009) The endoplasmic reticulum-associated degradation of transthyretin variants is negatively regulated by BiP in mammalian cells. J Biol Chem 284:8312\u20138321","journal-title":"J Biol Chem"},{"key":"10380_CR70","first-page":"11","volume-title":"ATF6 Activation Reduces Amyloidogenic Transthyretin Secretion through Increased Interactions with Endoplasmic Reticulum Proteostasis Factors","author":"JS Mesgarzadeh","year":"2022","unstructured":"Mesgarzadeh JS, Romine IC, Smith-Cohen EM, Grandjean JMD, Kelly JW, Genereux JC et al (2022) ATF6 activation reduces amyloidogenic transthyretin secretion through increased interactions with endoplasmic reticulum proteostasis factors. Cells, p 11"},{"key":"10380_CR71","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1096\/fj.11-189571","volume":"26","author":"JN Buxbaum","year":"2012","unstructured":"Buxbaum JN, Tagoe C, Gallo G, Walker JR, Kurian S, Salomon DR (2012) Why are some amyloidoses systemic? Does hepatic chaperoning at a distance prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J 26:2283\u20132293","journal-title":"FASEB J"},{"key":"10380_CR72","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-biochem-072711-163904","volume":"82","author":"AR Wyatt","year":"2013","unstructured":"Wyatt AR, Yerbury JJ, Ecroyd H, Wilson MR (2013) Extracellular chaperones and proteostasis. Annu Rev Biochem 82:295\u2013322","journal-title":"Annu Rev Biochem"},{"key":"10380_CR73","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/128_2011_262","volume":"328","author":"RA Dabbs","year":"2013","unstructured":"Dabbs RA, Wyatt AR, Yerbury JJ, Ecroyd H, Wilson MR (2013) Extracellular chaperones. Top Curr Chem 328:241\u2013268","journal-title":"Top Curr Chem"},{"key":"10380_CR74","doi-asserted-by":"publisher","first-page":"e0125392","DOI":"10.1371\/journal.pone.0125392","volume":"10","author":"G da Costa","year":"2015","unstructured":"da Costa G, Ribeiro-Silva C, Ribeiro R, Gilberto S, Gomes RA, Ferreira A et al (2015) Transthyretin amyloidosis: chaperone concentration changes and increased proteolysis in the pathway to disease. PLoS ONE 10:e0125392","journal-title":"PLoS ONE"},{"key":"10380_CR75","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86:1036\u20131043","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10380_CR76","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0968-0896(98)00130-8","volume":"6","author":"PW Baures","year":"1998","unstructured":"Baures PW, Peterson SA, Kelly JW (1998) Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem 6:1389\u20131401","journal-title":"Bioorg Med Chem"},{"key":"10380_CR77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1021\/jm030347n","volume":"47","author":"SL Adamski-Werner","year":"2004","unstructured":"Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW (2004) Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 47:355\u2013374","journal-title":"J Med Chem"},{"key":"10380_CR78","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"key":"10380_CR79","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","volume":"9","author":"C Rapezzi","year":"2021","unstructured":"Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ et al (2021) Efficacy of Tafamidis in patients with Hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail 9:115\u2013123","journal-title":"JACC Heart Fail"},{"key":"10380_CR80","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","volume":"583","author":"N Ferreira","year":"2009","unstructured":"Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, Bai G et al (2009) Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 583:3569\u20133576","journal-title":"FEBS Lett"},{"key":"10380_CR81","doi-asserted-by":"publisher","first-page":"e29933","DOI":"10.1371\/journal.pone.0029933","volume":"7","author":"N Ferreira","year":"2012","unstructured":"Ferreira N, Saraiva MJ, Almeida MR (2012) Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: in vivo evidence from FAP mice models. PLoS ONE 7:e29933","journal-title":"PLoS ONE"},{"key":"10380_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbadis.2012.10.007","volume":"1832","author":"N Ferreira","year":"2013","unstructured":"Ferreira N, Santos SA, Domingues MR, Saraiva MJ, Almeida MR (2013) Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. Biochim Biophys Acta 1832:39\u201345","journal-title":"Biochim Biophys Acta"},{"key":"10380_CR83","doi-asserted-by":"crossref","unstructured":"Ferreira N, Saraiva MJ, Almeida MR (2019) Uncovering the neuroprotective mechanisms of curcumin on transthyretin amyloidosis. Int J Mol Sci 20","DOI":"10.3390\/ijms20061287"},{"key":"10380_CR84","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jmb.2008.07.029","volume":"382","author":"SK Palaninathan","year":"2008","unstructured":"Palaninathan SK, Mohamedmohaideen NN, Snee WC, Kelly JW, Sacchettini JC (2008) Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. J Mol Biol 382:1157\u20131167","journal-title":"J Mol Biol"},{"key":"10380_CR85","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/13506120600960882","volume":"13","author":"Y Sekijima","year":"2009","unstructured":"Sekijima Y, Dendle MA, Kelly JW (2009) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13:236\u2013249","journal-title":"Amyloid"},{"key":"10380_CR86","doi-asserted-by":"crossref","unstructured":"Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy. JAMA 310","DOI":"10.1001\/jama.2013.283815"},{"key":"10380_CR87","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","volume":"26","author":"G Lohrmann","year":"2020","unstructured":"Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH et al (2020) Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail 26:753\u2013759","journal-title":"J Card Fail"},{"key":"10380_CR88","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM et al (2019) Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 74:285\u2013295","journal-title":"J Am Coll Cardiol"},{"key":"10380_CR89","unstructured":"Topline Results from Phase 3 ATTRibute-CM Study|BridgeBio. Available online: https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-month-12-topline-results-from-phase-3-attribute-cm-study\/. Accessed on 14 Oct 2023"},{"key":"10380_CR90","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV et al (2018) Patisiran, an RNAi therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"10380_CR91","unstructured":"Topline Results from APOLLO-B Phase 3 Study of Patisiran. Available online: https:\/\/alnylampharmaceuticalsinc.gcs-web.com\/static-files\/dc61b882-9346-4394-9f5c-dd322727742b. Accessed on 14 Oct 2023"},{"key":"10380_CR92","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF (2018) GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther 28:109\u2013118","journal-title":"Nucleic Acid Ther"},{"key":"10380_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plant\u00e9-Bordeneuve V, Berk JL et al (2023) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30:1\u20139","journal-title":"Amyloid"},{"key":"10380_CR94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK et al (2018) Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 379:22\u201331","journal-title":"N Engl J Med"},{"key":"10380_CR95","doi-asserted-by":"publisher","first-page":"12388","DOI":"10.1093\/nar\/gkx960","volume":"45","author":"M Tanowitz","year":"2017","unstructured":"Tanowitz M, Hettrick L, Revenko A, Kinberger GA, Prakash TP, Seth PP (2017) Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res 45:12388\u201312400","journal-title":"Nucleic Acids Res"},{"key":"10380_CR96","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","volume":"10","author":"T Coelho","year":"2021","unstructured":"Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ et al (2021) Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-L(rx) (ION-682884-CS3) in Hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther 10:375\u2013389","journal-title":"Neurol Ther"},{"key":"10380_CR97","unstructured":"Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis | Ionis Pharmaceuticals, Inc. Available online: https:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/ionis-presents-positive-results-phase-3-neuro-ttransform-study.\u00a0Accessed on 14 Oct 2023"},{"key":"10380_CR98","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon A, Hagenbuch A, Huy C, Varela E, Combaluzier B, Damy T et al (2021) A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun 12:3142","journal-title":"Nat Commun"},{"key":"10380_CR99","doi-asserted-by":"crossref","unstructured":"Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV et al (2023) Phase 1 trial of antibody NI006 for depletion of Cardiac Transthyretin amyloid. N Engl J Med","DOI":"10.1056\/NEJMoa2303765"},{"key":"10380_CR100","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","volume":"41","author":"J George","year":"2020","unstructured":"George J, Rappaport M, Shimoni S, Goland S, Voldarsky I, Fabricant Y et al (2020) A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model. Eur Heart J 41:1260\u20131270","journal-title":"Eur Heart J"},{"key":"10380_CR101","unstructured":"Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021. Available online: https:\/\/www.globenewswire.com\/en\/news-release\/2021\/04\/18\/2211990\/24041\/en\/Prothena-Presents-Phase-1-Study-Results-of-PRX004-in-Oral-Presentation-at-AAN-2021.html. Accessed on 14 Oct 2023"},{"key":"10380_CR102","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","volume":"4","author":"KW Zhang","year":"2019","unstructured":"Zhang KW, Stockerl-Goldstein KE, Lenihan DJ (2019) Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis. JACC Basic Transl Sci 4:438\u2013448","journal-title":"JACC Basic Transl Sci"},{"key":"10380_CR103","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1074\/jbc.RA118.005257","volume":"294","author":"L Saelices","year":"2019","unstructured":"Saelices L, Nguyen BA, Chung K, Wang Y, Ortega A, Lee JH et al (2019) A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. J Biol Chem 294:6130\u20136141","journal-title":"J Biol Chem"},{"key":"10380_CR104","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nbd.2018.09.007","volume":"120","author":"L Saelices","year":"2018","unstructured":"Saelices L, Pokrzywa M, Pawelek K, Eisenberg DS (2018) Assessment of the effects of transthyretin peptide inhibitors in drosophila models of neuropathic ATTR. Neurobiol Dis 120:118\u2013125","journal-title":"Neurobiol Dis"},{"key":"10380_CR105","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J et al (2018) A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 22:2227\u20132235","journal-title":"Cell Rep"},{"key":"10380_CR106","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG et al (2016) Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid 23:148\u2013157","journal-title":"Amyloid"},{"key":"10380_CR107","unstructured":"Intellia and Regeneron announce updated phase 1 data demonstrating a single dose of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis, resulted in rapid, deep and sustained reduction in disease-causing protein. Available online: https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/. Accessed on 14 Oct 2023"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10380-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T12:18:23Z","timestamp":1710764303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10380-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":107,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["10380"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10380-9","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"7 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}